Fig. 1.
Progression-free (solid line) and overall survival (dashed line) curves of 35 patients with recurrent glioblastoma in the phase II trial of romidepsin.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.